Schneck Pulmonology is now using the Food & Drug Administration-approved Spiration Valve System for the treatment of severe emphysema.

This innovation provides physicians an important new therapy for the treatment of adult patients who are suffering from the symptoms of severe emphysema, such as shortness of breath, according to a news release from Schneck Medical Center in Seymour.

The Spiration Valve System offers an option for patients who otherwise may have a poor prognosis. With this new technology, patients with late-stage COPD may improve their breathing and their lifestyle overall.

The Spiration Valve System is a minimally invasive procedure where expandable valves are inserted into damaged air sacs of the lungs. These valves reroute airflow to healthier regions of the lungs while also helping clear extraneous fluids. The spiration valves result in increased air capacity for the lungs with minimal recovery time for the patient.

Typically, candidates for the Spiration Valve System have been treated for late-stage COPD, have experienced inadequate or no response to medical management of their condition and are at high risk of complications from a traditional surgical procedure. Most eligible patients have Stage 3 or Stage 4 COPD.

“We are pleased to add the Spiration Valve System to our treatment portfolio for patients with severe emphysema,” Dr. David Wilson with Schneck Pulmonology said. “This advanced therapy gives patients an option to improve their quality of life and get back to doing the things they love.”

For information, call Schneck Pulmonology at 812-524-3328 or visit schneckmed.org.